Johnson & Johnson (NYSE:JNJ) Shares Sold by Brickley Wealth Management

Brickley Wealth Management cut its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 38.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,233 shares of the company’s stock after selling 774 shares during the period. Brickley Wealth Management’s holdings in Johnson & Johnson were worth $201,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. DORCHESTER WEALTH MANAGEMENT Co raised its stake in shares of Johnson & Johnson by 8.6% in the 1st quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 67,618 shares of the company’s stock valued at $14,975,000 after acquiring an additional 5,327 shares during the period. Cantor Fitzgerald Investment Advisor L.P raised its stake in shares of Johnson & Johnson by 88.9% in the 1st quarter. Cantor Fitzgerald Investment Advisor L.P now owns 175,194 shares of the company’s stock valued at $31,049,000 after acquiring an additional 82,429 shares during the period. AMI Investment Management Inc. raised its stake in shares of Johnson & Johnson by 8.8% in the 1st quarter. AMI Investment Management Inc. now owns 18,305 shares of the company’s stock valued at $3,244,000 after acquiring an additional 1,475 shares during the period. Equitable Holdings Inc. raised its stake in shares of Johnson & Johnson by 4.9% in the 1st quarter. Equitable Holdings Inc. now owns 45,673 shares of the company’s stock valued at $8,095,000 after acquiring an additional 2,119 shares during the period. Finally, USS Investment Management Ltd raised its stake in shares of Johnson & Johnson by 2.4% in the 1st quarter. USS Investment Management Ltd now owns 860,371 shares of the company’s stock valued at $152,488,000 after acquiring an additional 20,528 shares during the period. 67.94% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction on Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other Johnson & Johnson news, EVP Ashley Mcevoy sold 73,323 shares of the firm’s stock in a transaction on Wednesday, November 30th. The shares were sold at an average price of $175.47, for a total transaction of $12,865,986.81. Following the transaction, the executive vice president now directly owns 41,813 shares of the company’s stock, valued at approximately $7,336,927.11. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joseph J. Wolk sold 14,781 shares of the firm’s stock in a transaction on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the transaction, the chief financial officer now directly owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold 233,611 shares of company stock valued at $40,960,735 in the last ninety days. Insiders own 0.35% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on JNJ. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a research note on Thursday, November 17th. They issued a “neutral” rating and a $170.00 price target on the stock. Raymond James dropped their price objective on shares of Johnson & Johnson from $192.00 to $185.00 and set an “outperform” rating for the company in a report on Wednesday, October 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They issued a “strong-buy” rating for the company. Sanford C. Bernstein dropped their price objective on shares of Johnson & Johnson from $194.00 to $190.00 in a report on Wednesday, October 19th. Finally, Morgan Stanley dropped their price objective on shares of Johnson & Johnson from $178.00 to $176.00 and set an “equal weight” rating for the company in a report on Tuesday, December 6th. Seven research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $181.75.

Johnson & Johnson Trading Down 0.3 %

NYSE JNJ opened at $168.31 on Tuesday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.43 and a quick ratio of 1.18. The firm’s fifty day moving average price is $176.07 and its 200 day moving average price is $171.13. The company has a market capitalization of $440.04 billion, a price-to-earnings ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. The ex-dividend date of this dividend is Friday, February 17th. Johnson & Johnson’s dividend payout ratio (DPR) is 62.95%.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.